Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

[Q]: Context: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis. Three multicenter, randomized, double-masked, placebo-controlled, dose-ranging phase III studies: SHIELD, INSURE, and ENDURE. A total of 118 patients with Behcet's uveitis (SHIELD study); 31 patients with active, noninfectious, non-Behcet's uveitis (INSURE study); and 125 patients with quiescent, noninfectious, non-Behcet's uveitis (ENDURE study) were enrolled. After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2 weeks (q2w), secukinumab 300 mg monthly (q4w), or placebo in the SHIELD study; secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the INSURE study; or secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the ENDURE study. Reduction of uveitis recurrence or vitreous haze score during withdrawal of concomitant immunosuppressive medication (ISM). Other end points included best-corrected visual acuity, ISM use (expressed as a standardized ISM score), and safety outcomes. After completion or early termination of each trial, there were no statistically significant differences in uveitis recurrence between the secukinumab treatment groups and placebo groups in any study. Secukinumab was associated with a significant reduction in mean total post-baseline ISM score (P = 0.019; 300 mg q4w vs. placebo) in the SHIELD study. Likewise, secukinumab was associated with a greater median reduction in ISM score versus placebo in the INSURE study, although no statistical analysis of the difference was conducted because of the small sample size. Overall, there was no loss in visual acuity reported in any treatment group during follow-up in all 3 studies. According to descriptive safety statistics, the frequencies of ocular and nonocular adverse events seemed to be slightly higher among secukinumab groups versus placebo across the 3 studies. The primary efficacy end points of the 3 studies were not met. The secondary efficacy data from these studies suggest a beneficial effect of secukinumab in reducing the use of concomitant ISM. 
 Question: Which molecule is targeted by a monoclonal antibody Secukinumab?
[A]: interleukin-17a


[Q]: Context: Inventors are always looking for ways to make our lives easier, greener and a whole lot more fun. Take a look at the following breakthroughs in science and technology. What in the world will inventors dream up next? Superhero Suit Have you ever dreamed of becoming a superhero? Dream no more. There's a real Iron Man suit, XOS 2, which instantly transforms the person wearing it. The suit provides the power to lift 200 pounds with ease and break slabs of wood with a single karate chop. It was designed to help the military with heavy lifting. One person in the suit could do the work of three soldiers. Up, Up and Away! It took him 30 years to develop it, and now Glen Martin's invention is ready to take off. The Martin Jetpack allows its operator to fly 8,000 feet into the air. Unfortunately, you can't soar through the skies too long. The jetpack holds only 30 minutes' worth of fuel. The aircraft will sell for $100,000. Hardworking Robot The EMIEW2 robot is the perfect office helper. Need a document delivered? No problem! It can also guide visitors to their destinations. The three-foot-tall robot can identify different human voices and respond to commands. One day, it may serve as a receptionist or a security guard. Green Machine Say goodbye to gasoline! The AirPod car runs on air power. That means this car won't pollute the environment. A high-pressure air tank can fill the car in minutes. The three-wheeler can travel about 130 miles between fill-ups. Beef Power All aboard the beef train! Amtrak's Heartland Flyer runs partly on fuel that is made from cow fat. The goal is to reduce carbon emissions by 10%. The train travels between Oklahoma City, Oklahoma, and Fort Worth, Texas. Robo-Guard EMILY is a robotic, four-foot-long buoy . She can swim through riptides at up to 24 miles per hour. Her inventor, Tony Mulligan, says that's 15 times as fast as human lifeguards! EMILY is powered by a tiny electric pump and operated by remote control. 
 Question: How many environment-friendly inventions are mentioned in the passage?
[A]: three.


[Q]: Context: Richard Packard is an American physicist, a professor at the University of California, Berkeley, known for having built the first quantum gyroscope with his colleagues. 
 Question: What is Richard Packard's place of employment?
[A]:
university of california, berkeley